PURPOSE: Recent studies suggest that children <24 months with stage I favorable histology Wilms tumors <550 g [very low risk Wilms tumors (VLRWT)] have an excellent prognosis when treated with nephrectomy only, without adjuvant chemotherapy. The identification of risk categories within VLRWT may enable refinement of their definition and optimization of their therapy. EXPERIMENTAL DESIGN: To define biologically distinct subsets, global gene expression analysis was done on 39 VLRWT that passed all quality-control parameters and the clusters identified were validated in an independent set of 11 VLRWT. Validation of select differentially expressed genes was done with immunohistochemistry on a tissue microarray from 20 of 39 tumors. Loss of heterozygosity (LOH) for 11p15, 1p, and 16q was analyzed in 52 tumors using PCR. RESULTS: Two distinctive clusters were identified. One cluster included 9 tumors with epithelial differentiated tubular histology, paucity of nephrogenic rests, lack of LOH for 1p, 16q, and 11p, absence of relapse, and a unique gene expression profile consistent with arrest following mesenchymal-to-epithelial transition. The second cluster included 13 tumors with mixed histology, intralobar nephrogenic rests, and decreased expression of WT1. Three of 6 relapses occurred in this cluster. Of 43 informative tumors, 11p LOH was present in 5 of 5 relapses and 11 of 38 nonrelapses. CONCLUSIONS: Two subsets comprising a total of 56% of VLRWT are identified that have pathogenetic and molecular differences and apparent differences in risk for relapse. If these predictors can be prospectively validated, this would enable the refinement of clinical stratification and less arbitrary definition of VLRWT.
PURPOSE: Recent studies suggest that children <24 months with stage I favorable histology Wilms tumors <550 g [very low risk Wilms tumors (VLRWT)] have an excellent prognosis when treated with nephrectomy only, without adjuvant chemotherapy. The identification of risk categories within VLRWT may enable refinement of their definition and optimization of their therapy. EXPERIMENTAL DESIGN: To define biologically distinct subsets, global gene expression analysis was done on 39 VLRWT that passed all quality-control parameters and the clusters identified were validated in an independent set of 11 VLRWT. Validation of select differentially expressed genes was done with immunohistochemistry on a tissue microarray from 20 of 39 tumors. Loss of heterozygosity (LOH) for 11p15, 1p, and 16q was analyzed in 52 tumors using PCR. RESULTS: Two distinctive clusters were identified. One cluster included 9 tumors with epithelial differentiated tubular histology, paucity of nephrogenic rests, lack of LOH for 1p, 16q, and 11p, absence of relapse, and a unique gene expression profile consistent with arrest following mesenchymal-to-epithelial transition. The second cluster included 13 tumors with mixed histology, intralobar nephrogenic rests, and decreased expression of WT1. Three of 6 relapses occurred in this cluster. Of 43 informative tumors, 11p LOH was present in 5 of 5 relapses and 11 of 38 nonrelapses. CONCLUSIONS: Two subsets comprising a total of 56% of VLRWT are identified that have pathogenetic and molecular differences and apparent differences in risk for relapse. If these predictors can be prospectively validated, this would enable the refinement of clinical stratification and less arbitrary definition of VLRWT.
Authors: V Schumacher; S Schneider; A Figge; G Wildhardt; D Harms; D Schmidt; A Weirich; R Ludwig; B Royer-Pokora Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205
Authors: Wenliang Li; Patricia Kessler; Herman Yeger; Jennifer Alami; Anthony E Reeve; Rosemary Heathcott; Jane Skeen; Bryan R G Williams Journal: Cancer Res Date: 2005-04-01 Impact factor: 12.701
Authors: Maria Aparecida Azevedo Koike Folgueira; Dirce Maria Carraro; Helena Brentani; Diogo Ferreira da Costa Patrão; Edson Mantovani Barbosa; Mário Mourão Netto; José Roberto Fígaro Caldeira; Maria Lucia Hirata Katayama; Fernando Augusto Soares; Célia Tosello Oliveira; Luiz Fernando Lima Reis; Jane Haruko Lima Kaiano; Luiz Paulo Camargo; Ricardo Zorzetto Nicoliello Vêncio; Igor Moysés Longo Snitcovsky; Fabiana Baroni Alves Makdissi; Paulo José da Silva e Silva; João Carlos Guedes Sampaio Góes; Maria Mitzi Brentani Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Paul E Grundy; Norman E Breslow; Sierra Li; Elizabeth Perlman; J Bruce Beckwith; Michael L Ritchey; Robert C Shamberger; Gerald M Haase; Giulio J D'Angio; Milton Donaldson; Max J Coppes; Marcio Malogolowkin; Patricia Shearer; Patrick R M Thomas; Roger Macklis; Gail Tomlinson; Vicki Huff; Daniel M Green Journal: J Clin Oncol Date: 2005-08-29 Impact factor: 44.544
Authors: Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko Journal: Am J Pathol Date: 2004-12 Impact factor: 4.307
Authors: Elizabeth J Perlman; Paul E Grundy; James R Anderson; Lawrence J Jennings; Daniel M Green; Jeffrey S Dome; Robert C Shamberger; E Cristy Ruteshouser; Vicki Huff Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger Journal: Ann Surg Date: 2017-04 Impact factor: 12.969
Authors: Jeffrey S Dome; Elizabeth A Mullen; David B Dix; Eric J Gratias; Peter F Ehrlich; Najat C Daw; James I Geller; Murali Chintagumpala; Geetika Khanna; John A Kalapurakal; Lindsay A Renfro; Elizabeth J Perlman; Paul E Grundy; Conrad V Fernandez Journal: J Natl Compr Canc Netw Date: 2021-08-01 Impact factor: 11.908
Authors: Conrad V Fernandez; Elizabeth A Mullen; Yueh-Yun Chi; Peter F Ehrlich; Elizabeth J Perlman; John A Kalapurakal; Geetika Khanna; Arnold C Paulino; Thomas E Hamilton; Kenneth W Gow; Zelig Tochner; Fredric A Hoffer; Janice S Withycombe; Robert C Shamberger; Yeonil Kim; James I Geller; James R Anderson; Paul E Grundy; Jeffrey S Dome Journal: J Clin Oncol Date: 2017-12-06 Impact factor: 44.544
Authors: Jeffrey S Dome; Conrad V Fernandez; Elizabeth A Mullen; John A Kalapurakal; James I Geller; Vicki Huff; Eric J Gratias; David B Dix; Peter F Ehrlich; Geetika Khanna; Marcio H Malogolowkin; James R Anderson; Arlene Naranjo; Elizabeth J Perlman Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Lauren N Parsons; Elizabeth A Mullen; James I Geller; Yueh-Yun Chi; Geetika Khanna; Richard D Glick; Jennifer H Aldrink; Kelly L Vallance; Yeonil Kim; Conrad V Fernandez; Jeffrey S Dome; Elizabeth J Perlman Journal: Cancer Date: 2020-04-08 Impact factor: 6.860
Authors: Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh Journal: J Urol Date: 2016-05-31 Impact factor: 7.450
Authors: Samantha Gadd; Vicki Huff; Chiang-Ching Huang; E Cristy Ruteshouser; Jeffrey S Dome; Paul E Grundy; Norman Breslow; Lawrence Jennings; Daniel M Green; J Bruce Beckwith; Elizabeth J Perlman Journal: Neoplasia Date: 2012-08 Impact factor: 5.715